Targeting Classical EGFR Mutations in Lung Cancer: Twenty Years of Progress and Beyond

Area of Science:

• Oncology
• Genetics
• Pharmacology

Background:

• Activating epidermal growth factor receptor (EGFR) mutations significantly impact non-small cell lung cancer (NSCLC) management.
• Two decades of precision oncology advances have improved outcomes for EGFR-mutant NSCLC patients across various disease stages.
• Despite progress, treatment selection and sequencing remain challenging due to numerous therapeutic options.

Purpose of the Study:

• To provide a comprehensive review of contemporary data on managing classical EGFR-mutant NSCLC.
• To summarize novel therapeutic approaches, resistance strategies, and CNS-directed management.
• To discuss emerging treatments and future research priorities in EGFR-mutant NSCLC.

Main Methods:

• Narrative review of current literature and clinical data.
• Synthesis of information on therapeutic advances, resistance mechanisms, and treatment integration.
• Discussion of emerging technologies and personalized treatment strategies.

Main Results:

• Significant improvements in treatment outcomes for EGFR-mutant NSCLC.
• Identification of challenges in treatment selection and sequencing.
• Overview of novel therapeutic approaches and emerging resistance strategies.

Conclusions:

• EGFR mutations have transformed NSCLC management, leading to substantial therapeutic advances.
• Ongoing research is crucial for addressing knowledge gaps and optimizing treatment selection and sequencing.
• Future directions include exploring fourth-generation inhibitors, nucleic-acid delivery, and data-driven personalized medicine.